Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Markus Moehler,Mikhail Dvorkin,Mustafa Ozguroglu,Min Hee Ryu,Alina Muntean,Sara Lonardi,Marina Nechaeva,Arinilda Bragagnoli,Hasan Senol Coskun,Antonio Cubillo Gracian,Toshimi Takano,Rachel Wong,Howard Safran,Gina M. Vaccaro,Narikazu Boku,Ilaria Conti,Janet Hong,Huiling Xiong,Julien Taieb,Yung-Jue Bang

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

2020

278Background: We report the primary analysis of JAVELIN Gastric 100, which compared avelumab (anti–PD-L1) maintenance after 1L CTx vs continued CTx in patients (pts) with GC/GEJC. Methods: In this...

Keywords:

Gastroenterology
Cancer
Internal medicine
Avelumab
first line
Javelin
Gastroesophageal Junction
Medicine
Chemotherapy
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations